AffiliationDepartment of Radiation Oncology, Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada
MetadataShow full item record
AbstractHypofractionated radiation therapy regimens are well suited to the management of keratinocyte carcinomas. Most lesions are small, superficial and not close to critical organs at risk. Fewer visits to the cancer centre are advantageous for the frail and elderly patient population. No difference in cosmesis or local control has been found when comparing hypofractionated with conventionally fractionated radiation therapy schedules, although most of the data in the literature are retrospective, highlighting the need for prospective trials. As keratinocyte carcinomas can present anywhere on the skin surface, a wide variety of techniques may be used to optimise treatment delivery, including external beam radiation with kilovoltage, electron beams and megavoltage photons. Brachytherapy can also be used with radionuclide and electronic-based applicators, surface applicators and interstitial techniques for lesions >5 mm deep. Stereotactic body radiotherapy, or extreme hypofractionation, is an emerging treatment option that delivers an ablative dose to the tumour while minimising dose to organs at risk through precision planning and delivery techniques. Frail elderly patients with medically inoperable disease not suitable for conventionally fractionated radiation therapy may achieve durable locoregional control with dose escalation. Ongoing studies following local control and toxicity are warranted. The aim of this article is to provide clinical oncologists with an overview of hypofractionation for keratinocyte carcinomas.
CitationTsao MN, Barnes EA, Karam I, Rembielak A. Hypofractionated Radiation Therapy in Keratinocyte Carcinoma. Clinical Oncology. 2022 May;34(5):E218-E24. PubMed PMID: WOS:000821121800004.
- Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
- Authors: Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N, PACE Trial Investigators
- Issue date: 2019 Nov
- Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
- Authors: Bozorgmehr F, Chung I, Christopoulos P, Krisam J, Schneider MA, Brückner L, Mueller DW, Thomas M, Rieken S
- Issue date: 2020 Aug 26
- Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis.
- Authors: Zaorsky NG, Lee CT, Zhang E, Keith SW, Galloway TJ
- Issue date: 2017 Oct
- Hypofractionation for clinically localized prostate cancer.
- Authors: Hickey BE, James ML, Daly T, Soh FY, Jeffery M
- Issue date: 2019 Sep 3
- Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
- Authors: Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellén E, Franzén L, Nilsson P
- Issue date: 2019 Aug 3